{"id":{"repo_id":"mtu","oai_identifier":"oai:digitalcommons.mtu.edu:etdr-1504"},"canonical_url":"https://search.ndltd.org/etd/mtu/oai:digitalcommons.mtu.edu:etdr-1504","repository":{"repo_id":"mtu","name":"Michigan Technological University","base_url":"https://digitalcommons.mtu.edu/do/oai/"},"display":{"title":"DEVELOPMENT AND CHARACTERIZATION OF HISTIDINE-TAGGED HPV16 L2 AND MS2-ARGININE-TAGGED RECOMBINANT PROTEINS FOR DOWNSTREAM PROCESSES","abstract":"Human papillomaviruses (HPVs) are the most common sexually transmitted infections. Persistent infection with HPV can lead to anogenital cancers including head and neck cancers. Three prophylactic vaccines have been approved to prevent against some types of HPV infection. However, the vaccines are HPV-type specific and protect mostly against the HPV types included in the vaccines. To offer broader protection against more HPV types, studies in the field are developing candidate vaccines targeting a conserved minor capsid protein, L2. Nevertheless, reagents for developing and assessing L2 vaccines are limited. For example, antibodies to assess the antigenicity of some L2 epitopes are not available commercially and multivalent platforms to develop and purify clinical grade L2 antigens are limited. In this study, I developed and characterized the immunogenicity of a recombinant Histidine-tagged HPV16 L2 (amino acid 1-130) antigen. In addition to this, I explored the development of a multivalent display platform, a recombinant MS2-bacteriophage coat protein, with a C-terminal Arginine-tag for downstream purification using cation exchange chromatography. All Recombinant proteins (Histidine-tagged L2 and MS2-Arg tagged) were successfully expressed in bacteria. However, only Histidine-tagged L2 proteins were successfully purified in large quantity to homogeneity. Mice immunized with the Histidine-tagged L2 protein elicited anti-L2 IgG antibody titers greater than 103. The anti-L2 antibodies generated in this study will be valuable to researchers, in the field, developing L2 vaccines.","abstract_html":"Human papillomaviruses (HPVs) are the most common sexually transmitted infections. Persistent infection with HPV can lead to anogenital cancers including head and neck cancers. Three prophylactic vaccines have been approved to prevent against some types of HPV infection. However, the vaccines are HPV-type specific and protect mostly against the HPV types included in the vaccines. To offer broader protection against more HPV types, studies in the field are developing candidate vaccines targeting a conserved minor capsid protein, L2. Nevertheless, reagents for developing and assessing L2 vaccines are limited. For example, antibodies to assess the antigenicity of some L2 epitopes are not available commercially and multivalent platforms to develop and purify clinical grade L2 antigens are limited. In this study, I developed and characterized the immunogenicity of a recombinant Histidine-tagged HPV16 L2 (amino acid 1-130) antigen. In addition to this, I explored the development of a multivalent display platform, a recombinant MS2-bacteriophage coat protein, with a C-terminal Arginine-tag for downstream purification using cation exchange chromatography. All Recombinant proteins (Histidine-tagged L2 and MS2-Arg tagged) were successfully expressed in bacteria. However, only Histidine-tagged L2 proteins were successfully purified in large quantity to homogeneity. Mice immunized with the Histidine-tagged L2 protein elicited anti-L2 IgG antibody titers greater than 103. The anti-L2 antibodies generated in this study will be valuable to researchers, in the field, developing L2 vaccines.","abstract_has_math":false,"creators":["Alothaim, Tahiyat"],"institution":null,"degree_name":"Master of Science in Biological Sciences (MS)","degree_level":"Open Access Master's Thesis","degree_discipline":"Department of Biological Sciences","degree_department":null,"school":null,"contributors":["Ebenezer Tumban"],"advisors":[],"committee_chairs":[],"committee_members":["Chandrashekhar Joshi","Stephen Techtmann"],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:17:09Z","subjects":["Human papillomaviruses","HPV vaccine","purification","Tags","recombinant protein","VLPs","Diseases","Genetics and Genomics","Immunology and Infectious Disease","Microbiology","Virology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.mtu.edu/etdr/402"],"render_values":[{"text":"https://digitalcommons.mtu.edu/etdr/402","href":"https://digitalcommons.mtu.edu/etdr/402","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/10.37099/mtu.dc.etdr/402","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/10.37099/mtu.dc.etdr/402","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.mtu.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.mtu.edu%3Aetdr-1504","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Ebenezer Tumban"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Chandrashekhar Joshi","Stephen Techtmann"]},{"key":"dc:creator","label":"Author","values":["Alothaim, Tahiyat"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2018-06-30T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2017-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Department of Biological Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Open Access Master's Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science in Biological Sciences (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Human papillomaviruses","HPV vaccine","purification","Tags","recombinant protein","VLPs","Diseases","Genetics and Genomics","Immunology and Infectious Disease","Microbiology","Virology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["10.37099/mtu.dc.etdr/402","https://digitalcommons.mtu.edu/etdr/402"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Human papillomaviruses (HPVs) are the most common sexually transmitted infections. Persistent infection with HPV can lead to anogenital cancers including head and neck cancers. Three prophylactic vaccines have been approved to prevent against some types of HPV infection. However, the vaccines are HPV-type specific and protect mostly against the HPV types included in the vaccines. To offer broader protection against more HPV types, studies in the field are developing candidate vaccines targeting a conserved minor capsid protein, L2. Nevertheless, reagents for developing and assessing L2 vaccines are limited. For example, antibodies to assess the antigenicity of some L2 epitopes are not available commercially and multivalent platforms to develop and purify clinical grade L2 antigens are limited. In this study, I developed and characterized the immunogenicity of a recombinant Histidine-tagged HPV16 L2 (amino acid 1-130) antigen. In addition to this, I explored the development of a multivalent display platform, a recombinant MS2-bacteriophage coat protein, with a C-terminal Arginine-tag for downstream purification using cation exchange chromatography. All Recombinant proteins (Histidine-tagged L2 and MS2-Arg tagged) were successfully expressed in bacteria. However, only Histidine-tagged L2 proteins were successfully purified in large quantity to homogeneity. Mice immunized with the Histidine-tagged L2 protein elicited anti-L2 IgG antibody titers greater than 103. The anti-L2 antibodies generated in this study will be valuable to researchers, in the field, developing L2 vaccines."]},{"key":"dc:description.note","label":"Dc Description Note","values":["<p>The preface and footnote are not needed because we do not intend to publish the thesis.</p>"]},{"key":"dc:title","label":"Title","values":["DEVELOPMENT AND CHARACTERIZATION OF HISTIDINE-TAGGED HPV16 L2 AND MS2-ARGININE-TAGGED RECOMBINANT PROTEINS FOR DOWNSTREAM PROCESSES"]}]}],"canonical_facts":{"dc:contributor":["Ebenezer Tumban"],"dc:contributor.committeemember":["Chandrashekhar Joshi","Stephen Techtmann"],"dc:creator":["Alothaim, Tahiyat"],"dc:date.available":["2018-06-30T07:00:00Z"],"dc:date.created":["2017-01-01T08:00:00Z"],"dc:description.abstract":["Human papillomaviruses (HPVs) are the most common sexually transmitted infections. Persistent infection with HPV can lead to anogenital cancers including head and neck cancers. Three prophylactic vaccines have been approved to prevent against some types of HPV infection. However, the vaccines are HPV-type specific and protect mostly against the HPV types included in the vaccines. To offer broader protection against more HPV types, studies in the field are developing candidate vaccines targeting a conserved minor capsid protein, L2. Nevertheless, reagents for developing and assessing L2 vaccines are limited. For example, antibodies to assess the antigenicity of some L2 epitopes are not available commercially and multivalent platforms to develop and purify clinical grade L2 antigens are limited. In this study, I developed and characterized the immunogenicity of a recombinant Histidine-tagged HPV16 L2 (amino acid 1-130) antigen. In addition to this, I explored the development of a multivalent display platform, a recombinant MS2-bacteriophage coat protein, with a C-terminal Arginine-tag for downstream purification using cation exchange chromatography. All Recombinant proteins (Histidine-tagged L2 and MS2-Arg tagged) were successfully expressed in bacteria. However, only Histidine-tagged L2 proteins were successfully purified in large quantity to homogeneity. Mice immunized with the Histidine-tagged L2 protein elicited anti-L2 IgG antibody titers greater than 103. The anti-L2 antibodies generated in this study will be valuable to researchers, in the field, developing L2 vaccines."],"dc:description.note":["<p>The preface and footnote are not needed because we do not intend to publish the thesis.</p>"],"dc:identifier":["10.37099/mtu.dc.etdr/402","https://digitalcommons.mtu.edu/etdr/402"],"dc:subject":["Human papillomaviruses","HPV vaccine","purification","Tags","recombinant protein","VLPs","Diseases","Genetics and Genomics","Immunology and Infectious Disease","Microbiology","Virology"],"dc:title":["DEVELOPMENT AND CHARACTERIZATION OF HISTIDINE-TAGGED HPV16 L2 AND MS2-ARGININE-TAGGED RECOMBINANT PROTEINS FOR DOWNSTREAM PROCESSES"],"thesis:degree_discipline":["Department of Biological Sciences"],"thesis:degree_level":["Open Access Master's Thesis"],"thesis:degree_name":["Master of Science in Biological Sciences (MS)"]},"updated_at":"2026-11-19T08:17:09Z"}